InvestorsHub Logo

garynavarre

09/06/20 3:20 PM

#296970 RE: Cardiologymd #296967

The other article that I found mentioned dosing as a consideration on these cases. What is the recommended dose for Marine vs Reduce-It? If they are different and generic sales are skewed toward the Reduce-It doses, this may help prove Amarin's case.

garynavarre

09/06/20 3:40 PM

#296973 RE: Cardiologymd #296967

I just found some of the earlier discussion about this from yesterday. Can information be obtained on the type of doctor who is prescribing Vascepa? If it is mostly cardiologists or similar (Reduce-It) as opposed to gastroenterologists (Marine)-that also would help any infringement case.

rosemountbomber

09/06/20 3:41 PM

#296974 RE: Cardiologymd #296967

And if I understand it correctly, it sounds a lot easier than en banc or SC.

alm2

09/06/20 4:41 PM

#296983 RE: Cardiologymd #296967

Card and G
Agree with this as a valid line of attack
But see also re the Vascepa 2.0 impact of that could be very significant
Alm